You are here

kidney cancer

Bristol's Opdivo-Yervoy duo snares a quick FDA nod in first-line kidney cancer

Bristol's Opdivo-Yervoy duo snares a quick FDA nod in first-line kidney cancer

Fierce Pharma

Bristol-Myers Squibb

Flag link:

Pfizer strikes out on Inlyta expansion bid with postsurgery kidney cancer failure

Pfizer strikes out on Inlyta expansion bid with postsurgery kidney cancer failure

Fierce Pharma

renal cell carcinoma

Flag link:

Novartis offloads failed cancer drug to Oncology Venture

Novartis offloads failed cancer drug to Oncology Venture

Fierce Biotech

Oncology Venture

Flag link:

Roche hails another PhIII win on Tecentriq combo, reports promising kidney cancer data

Roche hails another PhIII win on Tecentriq combo, reports promising kidney cancer data

Endpoints

Flag link:

Merck & Co. and Eisai seek to undermine BMS’ position in kidney cancer treatment sector

Merck & Co. and Eisai seek to undermine BMS’ position in kidney cancer treatment sector

GoinPharma

Bristol-Myers Squibb

Flag link:

Merck, Eisai nab Keytruda-Lenvima 'breakthrough' in quickly crowding kidney cancer field

Merck, Eisai nab Keytruda-Lenvima 'breakthrough' in quickly crowding kidney cancer field

Fierce Pharma

Flag link:

Pfizer defends kidney-cancer position with Bavencio 'breakthrough'

Pfizer defends kidney-cancer position with Bavencio 'breakthrough'

Fierce Pharma

Flag link:

Pfizer, Exelixis cancer drugs get FDA approval for wider use

Pfizer, Exelixis cancer drugs get FDA approval for wider use

Reuters

Flag link:

Cancer Space Update: Label Expansion for Three Major Drugs

Cancer Space Update: Label Expansion for Three Major Drugs

Yahoo/Zacks.com

follicular lymphoma

Flag link:

Bristol-Myers Squibb could double patient numbers for Opdivo in kidney cancer

Bristol-Myers Squibb could double patient numbers for Opdivo in kidney cancer

Fierce Pharma

Bristol-Myers Squibb

Flag link:

Pfizer hits a snag in bid to jump-start Sutent's flagging kidney cancer sales

Pfizer hits a snag in bid to jump-start Sutent's flagging kidney cancer sales

Fierce Pharma

Flag link:

Ipsen focuses on oncology to keep growing

Ipsen focuses on oncology to keep growing

GoInPharma

Flag link:

Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale

Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale

Motley Fool

Bristol-Myers Squibb

Flag link:

Opdivo combo shows early survival benefit in kidney cancer

Opdivo combo shows early survival benefit in kidney cancer

BioPharma Dive

Bristol-Myers Squibb

Flag link:

Latest Immunotherapy Setback: Bristol Drugs Stumble in Kidney Cancer

Latest Immunotherapy Setback: Bristol Drugs Stumble in Kidney Cancer

Xconomy

Bristol-Myers Squibb

Flag link:

Aveo soars as long-beleaguered cancer drug nears approval

Aveo soars as long-beleaguered cancer drug nears approval

Fierce Biotech

Flag link:

Acceleron dumps dalantercept after kidney cancer trial fail

Acceleron dumps dalantercept after kidney cancer trial fail

Fierce Biotech

clinical trials

Flag link:

Roche says Phase II trial supports twin treatment for kidney cancer

Roche says Phase II trial supports twin treatment for kidney cancer

Yahoo/Reuters

Flag link:

What's Pfizer's Excuse for Not Buying Exelixis?

What's Pfizer's Excuse for Not Buying Exelixis?

Motley Fool

Flag link:

Pfizer and Bristol-Myers Squibb Could Face a Big Threat from Small Biotech Exelixis

Pfizer and Bristol-Myers Squibb Could Face a Big Threat from Small Biotech Exelixis

Motley Fool

Bristol-Myers Squibb

Flag link:

Pages